Resmetirom is the first and only FDA-approved oral therapy for NASH/MASH. Resmetirom is a thyroid hormone receptor-beta (THR-β) agonist which is the first & only US FDA approved diseases specific oral therapy indicated for the treatment of NASH/MASH with fibrosis (stages F2 to F3). It works through multiple pathways and where it works directly in the liver by stimulating THR-β to improve critical hepatic processes and reduce fibrosis. Resmetirom ensures broad response rate in NASH/MASH treatment & also ensures a favorable cardiovascular profile by reducing serum lipid profile.
Aristopharma offers high quality Resmetirom in the brand name of Livheal manufactured by US DMF grade raw material. Simple once daily dose (1 tablet once daily) of Resmetirom ensures higher patients’ convenience.
FR
DE